Physician
First Choice Pediatrics, INC
First Choice Pediatrics, INC was paid $18.68M by Medicaid between Jan 2018 and Mar 2022, across 70 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 28% of everything it billed.
33Billing provider infoFIRST CHOICE PEDIATRICS, INC
ORLANDO, FL 32807
ORLANDO, FL 32807
33aNPI1801955174assigned 12/06/2006
33bProvider typePediatrics Physician
28Total paid$18.68M
24GClaims651,131
24DCodes billed70
24AFirst – last monthJan 2018 – Mar 2022
Compared with peers
Next to other Pediatrics Physician providers in Florida
Rank by total paid#7 of 971
Median peer was paid$238K
This provider vs. median78×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,187 | $340K | |
| 2019 | 130,692 | $3.78M | |
| 2020 | 166,489 | $5.16M | |
| 2021 | 252,839 | $7.43M | |
| 2022 | 94,924 | $1.98M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 28% | 79,422 | 68,007 | $5.18M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 23% | 42,870 | 39,098 | $4.25M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 14% | 19,952 | 18,709 | $2.66M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 9.5% | 13,896 | 13,022 | $1.78M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 7.9% | 13,040 | 11,677 | $1.47M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 5.0% | 48,798 | 46,270 | $942K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.8% | 6,120 | 5,521 | $709K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.4% | 7,170 | 6,566 | $450K |
| 97802 | 2.1% | 37,071 | 35,215 | $387K | |
| 90461 | 1.4% | 26,178 | 24,626 | $255K | |
| 99383 | <1% | 953 | 918 | $123K | |
| 99188 | <1% | 9,377 | 8,484 | $96K |
58 more codes
| 99382 | <1% | 300 | $46K | |
| 92558 | <1% | 26,178 | $44K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,351 | $36K |
| 99384 | <1% | 244 | $33K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,307 | $31K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,685 | $27K |
| 99381 | <1% | 290 | $27K | |
| 90686 | <1% | 14,322 | $27K | |
| 85018 | <1% | 21,336 | $16K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 554 | $14K |
| 83655 | <1% | 5,049 | $13K | |
| 96160 | <1% | 37,288 | $12K | |
| 90716 | <1% | 3,482 | $7K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 156 | $7K |
| 90633 | <1% | 5,512 | $6K | |
| 0071A | <1% | 152 | $6K | |
| 90670 | <1% | 11,592 | $6K | |
| 90707 | <1% | 5,231 | $5K | |
| 90723 | <1% | 6,906 | $3K | |
| 90648 | <1% | 11,619 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 442 | $2K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 13 | $2K |
| 36416 | <1% | 29,089 | $2K | |
| 90651 | <1% | 2,352 | $1K | |
| 80061 | Lipid panel | <1% | 3,059 | $1K |
| 0001A | <1% | 17 | $643.14 | |
| 91307 | <1% | 318 | $542.72 | |
| 0072A | <1% | 15 | $501.16 | |
| 90734 | <1% | 670 | $461.72 | |
| 87807 | <1% | 141 | $427.02 | |
| 99072 | <1% | 78,202 | $313.34 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 5,467 | $300.00 |
| 96127 | <1% | 468 | $292.89 | |
| 90700 | <1% | 201 | $250.54 | |
| 99173 | <1% | 17,719 | $218.44 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 56 | $186.89 |
| A4928 | Surgical mask, per 20 | <1% | 663 | $162.92 |
| 90696 | <1% | 105 | $157.37 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 47 | $145.00 |
| 92567 | <1% | 39 | $128.55 | |
| 90681 | <1% | 1,897 | $84.02 | |
| 91300 | <1% | 14 | $77.61 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 57 | $71.36 |
| 88720 | <1% | 50 | $23.80 | |
| S9451 | Exercise classes, non-physician provider, per session | <1% | 37,876 | $19.03 |
| 82962 | <1% | 12 | $18.20 | |
| 81002 | <1% | 24 | $12.54 | |
| 94760 | <1% | 45 | $7.26 | |
| 3078F | 0% | 2,670 | $0.00 | |
| 90715 | 0% | 88 | $0.00 | |
| 86703 | 0% | 12 | $0.00 | |
| 3074F | 0% | 2,680 | $0.00 | |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 68 | $0.00 |
| 90620 | 0% | 25 | $0.00 | |
| 92587 | 0% | 53 | $0.00 | |
| S8301 | Infection control supplies, not otherwise specified | 0% | 18 | $0.00 |
| 90688 | 0% | 12 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 46 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPORTUGAL, CASSIA (PRESIDENT)